Research Analysts Issue Forecasts for EPRX Q1 Earnings

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Eupraxia Pharmaceuticals in a research note issued on Tuesday, March 17th. HC Wainwright analyst B. Folkes expects that the company will post earnings per share of ($0.23) for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ Q3 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.96) EPS, FY2027 earnings at ($0.91) EPS, FY2028 earnings at ($1.05) EPS and FY2029 earnings at ($0.42) EPS.

Several other brokerages also recently weighed in on EPRX. Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Lifesci Capital raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 11th. Zacks Research downgraded shares of Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Cantor Fitzgerald raised their price objective on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a research note on Thursday, January 15th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Eupraxia Pharmaceuticals Stock Down 6.6%

NASDAQ EPRX opened at $7.10 on Thursday. Eupraxia Pharmaceuticals has a 52 week low of $2.68 and a 52 week high of $9.32. The firm has a market capitalization of $255.32 million, a price-to-earnings ratio of -6.89 and a beta of 1.27. The company has a fifty day moving average of $8.26 and a two-hundred day moving average of $6.89.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its quarterly earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.21).

Institutional Trading of Eupraxia Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Ally Bridge Group NY LLC bought a new stake in Eupraxia Pharmaceuticals during the 3rd quarter valued at about $5,398,000. Guardian Partners Inc. bought a new position in Eupraxia Pharmaceuticals in the 3rd quarter worth about $147,000. Ingalls & Snyder LLC grew its stake in Eupraxia Pharmaceuticals by 58.9% in the 3rd quarter. Ingalls & Snyder LLC now owns 59,100 shares of the company’s stock worth $349,000 after acquiring an additional 21,900 shares in the last quarter. TCI Wealth Advisors Inc. purchased a new position in shares of Eupraxia Pharmaceuticals during the third quarter worth approximately $65,000. Finally, Quadrature Capital Ltd purchased a new position in shares of Eupraxia Pharmaceuticals during the second quarter worth approximately $61,000.

Eupraxia Pharmaceuticals News Roundup

Here are the key news stories impacting Eupraxia Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and maintained an $11 price target, which provides upside support for the stock despite the earnings cuts — MarketBeat EPRX Coverage
• Neutral Sentiment: Brokers published predictions ahead of EPRX’s Q2 earnings, adding near-term expectations but not reporting any definitive catalyst; this keeps near-term guidance uncertainty elevated. Brokers Offer Predictions for EPRX Q2 Earnings
• Neutral Sentiment: A short-interest report in the period shows effectively zero reported short interest (data appears anomalous), so short covering is unlikely to be a near-term price driver.
• Negative Sentiment: Zacks downgraded Eupraxia from “Hold” to “Strong Sell,” a formal negative signal that likely pressured the shares. Zacks Downgrade
• Negative Sentiment: HC Wainwright cut multiple near- and multi‑year EPS forecasts (FY2026–FY2029 and Q1/Q3 2026), materially lowering profitability outlooks even while keeping a Buy rating — this mix of lower forecasts and unchanged optimism may create investor skepticism. HC Wainwright Estimates
• Negative Sentiment: Lifesci Capital trimmed its FY2026 EPS forecast (now deeper negative), which adds to the consensus downside revisions despite Lifesci retaining a “Strong-Buy” stance.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.